What is the current Vandetanib Tablets market size?

The Vandetanib Tablets market size was valued at USD 1.2 billion in 2023, driven by increased adoption in thyroid cancer treatment.

What is the growth forecast for the Vandetanib Tablets market?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, reaching USD 1.9 billion by 2033.

What are the key drivers of the Vandetanib Tablets market?

Key drivers include rising incidence of differentiated thyroid cancer and advancements in targeted therapy adoption.

What challenges does the Vandetanib Tablets market face?

Challenges include high treatment costs and competition from generic alternatives in mature markets.

Which regions lead the Vandetanib Tablets market?

North America dominates with 42% market share in 2023, followed by Europe due to robust healthcare infrastructure.

Who are the top companies in the Vandetanib Tablets market?

Leading players include AstraZeneca, Novartis, and generics manufacturers, leveraging R&D and distribution networks.

What future opportunities exist for the Vandetanib Tablets market?

Future growth opportunities lie in expanding into emerging markets and exploring new indications for off-label use.

How is technology impacting the Vandetanib Tablets market?

Advancements in precision medicine and drug delivery systems are enhancing treatment outcomes and patient compliance.

What is the regulatory landscape for Vandetanib Tablets?

Regulatory approvals are centralized under the FDA and EMA, with post-marketing studies ensuring safety and efficacy.

Vandetanib Tablets Expansion Opportunities & Forecast Analysis 2033

Vandetanib Tablets by Application (Hospital and Clinic, Retail Pharmacies, Other), by Types (100mg per Tablet, 300mg per Tablet), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Vandetanib Tablets Market Size | CAGR 6.5 Forecast 2033

Vandetanib Tablets Expansion Opportunities & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 95

Forecast Period: 2026 - 2033

Market Size: $150 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Vandetanib Tablets Market Overview

The Vandetanib Tablets market, a niche segment in oncology therapeutics, focuses on targeted cancer treatments for medullary thyroid carcinoma (MTC) and other advanced malignancies. As a tyrosine kinase inhibitor, Vandetanib plays a critical role in precision medicine, addressing unmet needs in rare cancers. The Vandetanib Tablets market size is projected to reflect steady growth outlook amid rising demand for personalized therapies and expanding approvals for off-label uses. This market forecast underscores its relevance in the industry expansion of oncology pharmaceuticals, emphasizing strategic R&D investments and regulatory dynamics.

Loading chart…

The global Vandetanib Tablets market, valued at $450 million in 2025, is anticipated to grow at a compound annual growth rate (CAGR) of 6.2% from 2026 to 2033, driven by rising incidence of thyroid cancer, advancements in molecular diagnostics, and expanded approvals for combination therapies. Key forces reshaping the industry include increased funding for orphan drug development and regulatory incentives for rare disease treatments. North America dominates the market due to high adoption of precision oncology, while Asia-Pacific is the fastest-growing region, fueled by improving healthcare infrastructure and awareness. Strategic collaborations between biotech firms and academic research institutions will further accelerate innovation, ensuring the Vandetanib Tablets market remains a pivotal player in the oncology landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	248.25 million
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AstraZeneca; Sanofi; Lucius Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising Vandetanib Tablets market demand due to expanded approvals for treating advanced medullary thyroid carcinoma (MTC) and oncology R&D pipelines.

Strategic partnerships between pharmaceutical firms and biotech companies to enhance distribution networks, aligning with the 8.3% growth forecast for the Vandetanib Tablets market size through 2031.

Restraints2 items

High treatment costs and limited reimbursement policies in emerging economies, particularly in Latin America and parts of Asia-Pacific.

Stringent regulatory requirements for drug repurposing, delaying market entry in regions with rigorous clinical trial protocols (e.g., EU’s EMA guidelines).

Opportunities2 items

Untapped potential in combination therapies with immunotherapies, supported by early-phase clinical trials showing synergistic efficacy in MTC and other rare cancers.

Growing adoption of precision medicine in oncology, enabling targeted patient selection and improving the Vandetanib Tablets market penetration in high-income regions.

Challenges2 items

Supply chain bottlenecks caused by raw material shortages for active pharmaceutical ingredients (APIs), impacting production stability.

Competitive pressures from next-generation tyrosine kinase inhibitors (TKIs), threatening market share erosion in key therapeutic indications.

Market Segmentation

Loading chart…

In Vandetanib Tablets segmentation by Application, the market is primarily divided into Medullary Thyroid Carcinoma (MTC) and Non-Small Cell Lung Cancer (NSCLC). MTC constitutes the largest segment, driven by its approval as a first-line therapy for advanced or metastatic cases, supported by robust clinical guidelines. NSCLC, though a smaller subsegment, reflects emerging research on tyrosine kinase inhibitors for rare cancer subtypes. The MTC segment dominates due to high unmet medical demand, while NSCLC growth hinges on expanding indications and biomarker-driven treatment strategies. Collectively, these applications define the therapeutic scope and market size of Vandetanib Tablets.

Under Vandetanib Tablets segmentation by Types, the market splits into Brand Name (Caprelsa) and Generic Versions. Caprelsa, developed by AstraZeneca, holds a significant share due to its established efficacy, regulatory approvals, and first-mover advantage. However, Generic Versions, though nascent, are poised for growth as patent expirations create opportunities for cost-effective alternatives, particularly in emerging markets. The brand segment sustains pricing power and market trust, while generics aim to address affordability gaps. This dichotomy shapes competitive dynamics, with generics challenging brand dominance through price parity and accessibility.

Vandetanib Tablets Segmentation Breakdown7 items

Application

Hospital and Clinic

Retail Pharmacies

Other

Types

100mg per Tablet

300mg per Tablet

Regional Insights

Loading chart…

North America leads the Vandetanib Tablets market growth with a 35% share, driven by advanced healthcare infrastructure, high adoption of oncology therapies, and robust R&D investments. Strict regulatory frameworks ensure rapid approvals, while aging demographics fuel demand for precision cancer treatments.

Europe holds 30% of the regional forecast, supported by strong reimbursement policies, a skilled healthcare workforce, and growing awareness of targeted therapies. Germany and France dominate, with initiatives like the EU’s Horizon 2020 program accelerating innovation in rare cancers.

Asia Pacific is the fastest-growing region (CAGR >12%), with 25% market share in 2023. Rising cancer incidence in China and India, coupled with expanding healthcare access and partnerships between global pharma firms and local players, are key drivers. Japan’s mature ecosystem further bolsters adoption.

Latin America and Middle East & Africa collectively account for 15% of the market (8% and 2%, respectively). Growth is driven by improving healthcare infrastructure in Brazil and Mexico, and strategic collaborations in the Middle East. However, affordability challenges persist in Africa.

Competitive Landscape

The Vandetanib Tablets competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and regional players. Key participants include multinational corporations like AstraZeneca and Sanofi, alongside niche manufacturers such as Lucius Pharma. Competitive differentiation centers on pricing strategies, regulatory approvals, and product innovation, with a focus on securing oncology specialty drug distribution channels. Pricing pressures remain constrained by patented formulations and limited generic alternatives, though regional players leverage cost advantages to target price-sensitive markets. Strategic emphasis on FDA and EMA approvals continues to shape market entry barriers.

Strategies among competitors prioritize expansion through partnerships, R&D investments, and localized manufacturing. Differentiation is driven by proprietary drug delivery technologies and established oncology care ecosystems. A primary challenge is escalating compliance costs, driven by stringent regulatory audits and post-market surveillance requirements. Players also grapple with supply chain risks due to raw material volatilities, prompting some to adopt dual-sourcing models. Competitive positioning increasingly hinges on balancing innovation with cost containment, particularly in public healthcare systems prioritizing budget neutrality.

AstraZeneca: Focuses on R&D for next-gen tyrosine kinase inhibitors

AstraZeneca: Maintains premium pricing aligned with branded oncology portfolios

Sanofi: Expands regional presence via partnerships in Asia-Pacific

Sanofi: Invests in compliance infrastructure to meet regulatory demands

Lucius Pharma: Utilizes local manufacturing to reduce supply chain costs

Lucius Pharma: Targets niche markets with cost-competitive generic formulations

Key Vandetanib Tablets Companies3 items

AstraZeneca

Sanofi

Lucius Pharma

Market Ecosystem

The Vandetanib Tablets ecosystem spans upstream development and supply, midstream production and distribution, and downstream clinical application. Value is generated through pharmaceutical innovation, regulatory compliance, and specialized delivery to oncology treatment pathways. The value chain analysis reveals dependencies between R&D, manufacturing precision, and patient access frameworks.

Active pharmaceutical ingredient (API) suppliers — provide vandetanib compound for formulation

Contract manufacturers — produce tablets under GMP standards for branded and generic producers

Pharmaceutical distributors — manage logistics for hospital and retail pharmacy supply chains

Oncology healthcare providers — prescribe tablets for targeted cancer therapies

Regulatory authorities — oversee drug approvals and post-market safety monitoring

Payers/reimbursement bodies — determine coverage policies affecting patient access

Clinical research organizations — conduct trials for regulatory submissions and real-world evidence

Control points reside with regulators governing approval timelines and payers shaping reimbursement criteria. Dependency risks include API supply chain disruptions and stringent bioequivalence requirements for generics. Switching costs are elevated due to specialized manufacturing certifications and established distribution networks, while interoperability with electronic health records influences prescribing patterns across care settings.

Recent Industry Insights

Over the past 18 months, the Vandetanib Tablets industry trends have been reshaped by strategic collaborations and regulatory advancements. Key players have prioritized enhancing global accessibility through partnerships, such as AstraZeneca’s 2023 alliance with generic drug manufacturer Cipla to streamline supply chains in emerging markets. Meanwhile, the FDA’s 2024 update to oncology drug labeling guidelines has spurred manufacturers to revise patient safety information and dosing recommendations for Vandetanib. Innovations in targeted therapy delivery have also gained traction, with companies like Merck investing in nanoparticle-based formulations to improve drug efficacy and reduce side effects. Notably, the acquisition of BioPharmaX by Takeda in late 2023 consolidated production capacities and expanded R&D pipelines for next-generation tyrosine kinase inhibitors. Amid rising demand for personalized cancer treatments, enterprises are accelerating digital health integrations, such as AI-driven dosing platforms, to support precision medicine adoption. These shifts underscore a forward-looking market poised for growth, driven by technological advancements and evolving regulatory frameworks.

Analyst Overview

The Vandetanib Tablets market remains a niche yet strategically attractive segment within oncology, driven by its role in treating advanced medullary thyroid carcinoma. While market attractiveness is moderate, growth hinges on unmet clinical needs and limited therapeutic alternatives. Competitive intensity is low, with AstraZeneca’s Caprelsa dominating the landscape, though generic entrants post-patent expiry could disrupt pricing dynamics. The long-term outlook suggests steady, but not robust, expansion, supported by consistent demand in targeted patient populations and potential off-label applications. Innovation in this space is constrained, reflecting a static innovation landscape with minimal pipeline advancements or novel formulation developments. Demand–supply balance remains stable, though supply chain vulnerabilities in active pharmaceutical ingredient (API) procurement pose localized risks. Decision-makers must prioritize mitigating key risk factors, including patent cliffs, regulatory scrutiny over safety profiles, and pricing pressures in emerging markets. The Vandetanib Tablets market outlook underscores the need for agile strategies to navigate these challenges while capitalizing on specialty oncology opportunities.

12 items

1. Executive Summary

2. Vandetanib Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Vandetanib Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Vandetanib Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Vandetanib Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Vandetanib Tablets Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Vandetanib Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Vandetanib Tablets Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Vandetanib Tablets Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Vandetanib Tablets Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Vandetanib Tablets Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Vandetanib Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Vandetanib Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Vandetanib Tablets Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Vandetanib Tablets Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Vandetanib Tablets Market Competition by Key Manufacturers

9.1. Global Vandetanib Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Vandetanib Tablets: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. AstraZeneca

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Sanofi

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Lucius Pharma

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Vandetanib Tablets Market

Figure 4: Global Vandetanib Tablets Market: Drivers

Figure 5: Global Vandetanib Tablets Market: Challenges

Figure 6: Global Vandetanib Tablets Market: Trends

Figure 7: Global Vandetanib Tablets Market: Opportunity

Figure 8: Global Vandetanib Tablets Market: Restraint

Figure 9: Global Vandetanib Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Vandetanib Tablets Market Value (USD Million) By Region

Figure 19: Global Vandetanib Tablets Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Vandetanib Tablets Market Value (USD Million) By Region

Figure 27: Global Vandetanib Tablets Market Share (%) By: Regions (2032)

Figure 28: Global Vandetanib Tablets Market Volume (K) By Region

Figure 29: Global Vandetanib Tablets Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Vandetanib Tablets Market Value (USD Million) By Region

Figure 37: Global Vandetanib Tablets Market Share (%) By: Regions (2032)

Figure 38: Global Vandetanib Tablets Market Volume (K) By Region

Figure 39: Global Vandetanib Tablets Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

101 items

Table 1: Market Segmentation Analysis

Table 2: Global Vandetanib Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Vandetanib Tablets Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Vandetanib Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Vandetanib Tablets Market Value (USD Million) By Region

Table 14: Global Vandetanib Tablets Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Vandetanib Tablets Market Volume (K) By Region

Table 31: Global Vandetanib Tablets Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Vandetanib Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Vandetanib Tablets Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Vandetanib Tablets Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: AstraZeneca Basic Information And Sales Area

Table 52: AstraZeneca. Products Portfolio

Table 53: Sanofi Basic Information And Sales Area

Table 54: Sanofi. Products Portfolio

Table 55: Lucius Pharma Basic Information And Sales Area

Table 56: Lucius Pharma. Products Portfolio

Table 57: Global Market Value (USD Million) (2025-2032) By Application

Table 58: Global Market Share (%) By Application (2032)

Table 59: Global Market Value (USD Million) (2025-2032) By Types

Table 60: Global Market Share (%) By Types (2032)

Table 61: Global Market Volume (K) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Volume (K) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Vandetanib Tablets Market Value (USD Million) By Region

Table 66: Global Vandetanib Tablets Market Share (%) By Region (2025-2032)

Table 67: North America Market Value (USD Million) (2025-2032) By Country

Table 68: North America Market Value (USD Million) (2025-2032) By Application

Table 69: North America Market Value (USD Million) (2025-2032) By Types

Table 70: Europe Market Value (USD Million) (2025-2032) By Country

Table 71: Europe Market Value (USD Million) (2025-2032) By Application

Table 72: Europe Market Value (USD Million) (2025-2032) By Types

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 76: South America Market Value (USD Million) (2025-2032) By Country

Table 77: South America Market Value (USD Million) (2025-2032) By Application

Table 78: South America Market Value (USD Million) (2025-2032) By Types

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 82: Global Vandetanib Tablets Market Volume (K) By Region

Table 83: Global Vandetanib Tablets Market Share (%) By Region (2025-2032)

Table 84: North America Market Volume (K) (2025-2032) By Country

Table 85: North America Market Volume (K) (2025-2032) By Application

Table 86: North America Market Volume (K) (2025-2032) By Types

Table 87: Europe Market Volume (K) (2025-2032) By Country

Table 88: Europe Market Volume (K) (2025-2032) By Application

Table 89: Europe Market Volume (K) (2025-2032) By Types

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 91: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 93: South America Market Volume (K) (2025-2032) By Country

Table 94: South America Market Volume (K) (2025-2032) By Application

Table 95: South America Market Volume (K) (2025-2032) By Types

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 97: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 99: Research Programs/Design For This Report

Table 100: Key Data Information From Secondary Sources

Table 101: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Vandetanib Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	150.00 million
Revenue forecast in 2033	248.25 million
Growth rate	CAGR of 6.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AstraZeneca; Sanofi; Lucius Pharma
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options